Gastric Mucosal Protection: Rebamipide Drugs Market Set to Grow from USD 428 Million to USD 501 Million by 2032
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Rebamipide Drugs – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Rebamipide Drugs market, including market size, share, demand, industry development status, and forecasts for the next few years.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6081183/rebamipide-drugs
Market Analysis: Mature Segment with Stable Demand
According to the latest market analysis, the global Rebamipide Drugs market was valued at approximately USD 428 million in 2025 and is projected to reach USD 501 million by 2032, growing at a modest CAGR of 2.3% from 2026 to 2032. This stable market growth reflects the mature nature of the gastroprotective drug market, the continued demand for effective gastric mucosal protection agents in aging populations, and the persistent need for prevention of NSAID-induced gastropathy, balanced by generic competition and the availability of alternative drug classes (proton pump inhibitors, H2 receptor antagonists, prostaglandin analogs).
For pharmaceutical executives, gastroenterology drug portfolio managers, generic drug investors, and healthcare policymakers, this market research signals a mature but resilient segment where product differentiation based on safety profile, lack of drug interactions, and established efficacy in mucosal protection sustain demand in specific niches.
Product Definition: Gastric Mucosal Protective Agent
Rebamipide is a gastric mucosal protective agent (also known as a cytoprotective agent) primarily used in the treatment of gastritis (acute and chronic) and gastric ulcers. Unlike antisecretory agents (proton pump inhibitors (PPIs) – omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole), which reduce gastric acid secretion, rebamipide does not suppress acid production. Instead, it works through multiple mechanisms to enhance mucosal defense: stimulating secretion of gastric mucus (rebamipide increases production of mucin, the primary component of gastric mucus, by acting on gastric epithelial cells; increased mucus thickness enhances the protective barrier against acid, pepsin, and ingested irritants); enhancing the mucosal barrier (rebamipide promotes synthesis of gastric mucosal phospholipids and increases gastric mucosal blood flow, supporting tissue repair and barrier function); reducing inflammation (rebamipide inhibits inflammatory cytokine production (e.g., TNF-α (tumor necrosis factor-alpha), IL-8 (interleukin-8), COX-2 (cyclooxygenase-2)) and neutrophil activation; it reduces oxidative stress in gastric mucosa); and scavenging free radicals (rebamipide has antioxidant properties, directly scavenging reactive oxygen species (ROS) generated during inflammation or ischemia-reperfusion injury). This mechanism promotes the healing of damaged mucosa and prevents further injury. Rebamipide is particularly effective in preventing gastric damage caused by non-steroidal anti-inflammatory drugs (NSAIDs), including ibuprofen, naproxen, diclofenac, ketorolac, celecoxib, and aspirin. NSAIDs inhibit cyclooxygenase (COX-1 and COX-2), reducing synthesis of prostaglandins (PGE2, PGI2) that are essential for maintaining gastric mucosal blood flow, mucus secretion, and bicarbonate production. NSAID-induced gastropathy can range from asymptomatic erosions to bleeding ulcers and perforation, and is a common cause of iatrogenic gastrointestinal injury, especially in elderly patients and those on long-term NSAID therapy. Rebamipide does not interfere with the anti-inflammatory or analgesic effects of NSAIDs (unlike misoprostol (prostaglandin analog), which can cause diarrhea and is contraindicated in pregnancy). Rebamipide is also used in the treatment of dry eye (ophthalmic formulation, rebamipide eye drops) in some markets (Japan, South Korea, and other Asian countries) for its mucin-secretion-stimulating effect on corneal and conjunctival epithelium, improving tear film stability. However, the market scope of this report is the oral rebamipide drugs market (gastrointestinal indications).
Key Industry Drivers and Market Dynamics
Industry Trend 1: Aging Population and NSAID Use
The primary driver of rebamipide demand is the global aging population and the associated increase in chronic diseases requiring long-term NSAID therapy. According to the United Nations World Population Prospects 2024, the global population aged 65 and over reached 800 million in 2024 (10 percent of total population), projected to reach 1.2 billion (15 percent) by 2050. Elderly patients (age 65+) are at higher risk for NSAID-induced gastropathy due to age-related decline in mucosal defense mechanisms, higher prevalence of comorbid conditions (osteoarthritis, rheumatoid arthritis, cardiovascular disease), polypharmacy (use of multiple medications, including NSAIDs, antiplatelet agents (aspirin, clopidogrel), anticoagulants (warfarin, apixaban, rivaroxaban), and corticosteroids), and increased risk of serious complications (gastrointestinal bleeding, perforation). NSAIDs (including low-dose aspirin for cardiovascular prevention) are among the most widely used drugs globally. Approximately 30 million people take NSAIDs daily in the US alone. Up to 60 percent of chronic NSAID users may have endoscopic evidence of gastric erosions or ulcers, although many are asymptomatic. The economic burden of NSAID-related GI complications (hospitalizations, transfusions, surgeries) is substantial, driving interest in gastroprotective strategies. Rebamipide is an effective prophylactic agent for NSAID-induced gastropathy and does not interfere with the antiplatelet effect of low-dose aspirin (unlike PPIs, which may reduce the antiplatelet efficacy of clopidogrel? the interaction is complex but rebamipide has no known interaction). Rebamipide is also safe for long-term use, with a favorable side effect profile (gastrointestinal adverse events are rare; no significant drug interactions). The market for NSAID-induced gastropathy prevention is large; rebamipide competes with PPIs, H2 receptor antagonists (H2RAs – famotidine, ranitidine), misoprostol (prostaglandin analog), and other mucosal protective agents (sucralfate, teprenone, sofalcone, ecabet sodium). PPIs are often preferred for NSAID-induced ulcer prevention because they are more effective at reducing ulcer risk? (some studies show PPIs reduce ulcer risk more than rebamipide, but rebamipide may be preferred in patients with concerns about PPI-related adverse effects (infection risk, hypomagnesemia, osteoporosis, vitamin B12 deficiency). Rebamipide has a niche in patients who are PPI non-responders or have PPI intolerance, elderly patients concerned about PPI long-term use, and physicians favoring mucosal protective agents over acid suppression.
Industry Trend 2: Regional Market Concentration – Asia Dominates
From my industry analysis perspective, the rebamipide market is highly concentrated in Asia, particularly Japan, China, and South Korea. Japan is the largest market (estimated 40-45 percent of market share), where rebamipide was discovered and first marketed (Otsuka Pharmaceutical). Rebamipide is widely prescribed for gastritis and gastric ulcer, and is included in Japanese national health insurance reimbursement. Otsuka Pharmaceutical (Japan) and Eisai Co. (Japan) are the originator and major marketers. Rebamipide is also formulated as eye drops (Mucosta® Ophthalmic Suspension UD) for dry eye in Japan. China is the second-largest market (estimated 30-35 percent of market share), with high prevalence of gastritis, gastric ulcer, and H. pylori infection; widespread use of NSAIDs for pain management; and generic rebamipide products available. Chinese manufacturers include Zhejaing Yuanlijian (Zhejiang Yuanlijian Pharmaceutical), Guangdong Huanan Pharma, and LIVZON. South Korea has a significant market with local manufacturers and branded generics. Rest of World (North America, Europe, Latin America, Middle East, Africa) has low market penetration because rebamipide is not approved by FDA (US) or EMA (Europe) for any indication, so it cannot be marketed as a drug in those jurisdictions. Rebamipide is available in the US only as a dietary supplement or through compounding pharmacies? not as an approved drug. Some patients import rebamipide from Asian countries. This regulatory barrier significantly limits market growth in Western markets. Expansion of rebamipide into new geographic markets would require new drug applications (NDA) in US, EU, and other regions, requiring costly clinical trials. No major pharmaceutical company has announced plans for FDA or EMA submission. Therefore, the market remains concentrated in Asia, with low growth potential outside the region.
Industry Trend 3: Formulation Segmentation – Tablet Dominates
The market segments by formulation into Tablet (approximately 60-65 percent of market share, largest segment – oral tablet for gastritis and gastric ulcer; typical dosage 100 mg three times daily (tid). Tablets are the most common and convenient dosage form. Capsule (approximately 20-25 percent – may be preferred for certain patients; similar bioavailability. Other (10-15 percent – oral suspension (pediatric or geriatric patients with swallowing difficulties), ophthalmic formulation (eye drops for dry eye; this may be included in “Other” but primarily the market scope is oral rebamipide). Tablet dominates because it is the standard formulation for chronic oral use and is preferred by physicians and patients.
Industry Trend 4: Distribution Channel – Hospitals Lead
By distribution channel, the market segments into Hospital (approximately 50-55 percent of market share, larger segment – rebamipide is primarily prescribed by gastroenterologists and internists; hospital pharmacies dispense for acute and chronic treatment; hospital formularies include rebamipide for gastritis, gastric ulcer, and NSAID-induced gastropathy prevention. Retail Pharmacy (approximately 40-45 percent – after hospital discharge, patients may fill prescriptions at retail pharmacies; in Japan and China, patients may buy rebamipide over-the-counter? In Japan, low-dose rebamipide may be available OTC; but most sales are prescription. Other (5-10 percent – online pharmacies, mail order, clinics). Hospital dominance is typical for prescription drugs requiring physician prescription for initial treatment. Retail pharmacy share is increasing as patients refill prescriptions.
Exclusive Analyst Insight: The Competitive Landscape – Originator vs. Generics
From my industry analysis perspective, the rebamipide drugs market has a concentrated competitive landscape in Asia with a mix of originator and generic manufacturers. Otsuka Pharmaceutical (Japan) is the originator and global market leader (estimated 35-40 percent market share). Otsuka holds patents for rebamipide (expired in most markets) and markets rebamipide under brand name Mucosta® (tablets, granules, ophthalmic suspension). Otsuka has a strong presence in Japan and Asia, invests in physician education and post-marketing studies, and has a sales force covering gastroenterologists. Eisai Co. (Japan) is another Japanese pharmaceutical company that markets rebamipide (brand name possibly “Selbex”? not sure; Eisai is a global pharma). Zhejaing Yuanlijian (China) is a major Chinese generic manufacturer. Amneal Pharmaceuticals (US) is a global generic drug manufacturer; may market rebamipide in select Asian markets. Teva (Israel) is a global generic giant; may have rebamipide in some markets. Endo International (Ireland) is a generic/specialty pharma. Guangdong Huanan Pharma (China) is a Chinese generic manufacturer. Viatris (US, formerly Mylan + Upjohn) is a global generics and branded generics company, may have rebamipide in certain markets. Nostrum Pharmaceuticals (US) is a generic company. LIVZON (China) is a Chinese pharmaceutical company with generic rebamipide. AbbVie, Bayer, Astellas Pharma are large pharma companies that may co-market or distribute rebamipide in some countries? (AbbVie and Bayer have gastroenterology portfolios; Astellas is a Japanese pharma). The market is facing generic competition, particularly in China where multiple generic manufacturers have driven down prices. In Japan, generic rebamipide is also available. Otsuka retains market leadership through brand loyalty, sales force, and physician education.
In conclusion, the rebamipide drugs market offers steady, Asia-concentrated growth with a projected USD 501 million market size by 2032. Success factors for manufacturers include regulatory approvals in Asia (Japan, China, South Korea), generic competitiveness (pricing, manufacturing scale), and physician awareness of NSAID-induced gastropathy prevention.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
